News & events
%202.jpg)
Announcements
New ThirtyFiveBio Sponsored Systematic Review Evaluates Barrier Integrity Tools in IBD
At ECCO26, ThirtyFiveBio has enabled a team of leading clinicians to meet to evaluate the frontline of gut health. They have published a systematic review in AJP-Gastrointestinal: “Methods for Assessing Intestinal Barrier Function in Patients with IBD.” This systematic review aims to transition IBD care from managing symptoms to the precise measurement and restoration of true mucosal integrity.
Press Releases
ThirtyFiveBio Closes Bridge Round of Financing Highlighted by Strategic New Investment from AbbVie Ventures
ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced that the company has been awarded a highly competitive Biomedical Catalyst (BMC) grant from Innovate UK, the UK’s innovation agency.
.png)
Announcements
ThirtyFiveBio welcomes Donmienne Leung, of AbbVie Ventures to their Board of Directors
We are delighted to announce the appointment of Donmienne Leung, Director at AbbVie Ventures, to the Board of Directors at ThirtyFiveBio, alongside Annette Schwartz from AbbVie Inc. joining our scientific advisors. ThirtyFiveBio are better positioned than ever to accelerate our work and bring new solutions to patients who need them.
Press Releases
ThirtyFiveBio Awarded Second Grant by Innovate UK for £643k
ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced that the company has been awarded a highly competitive Biomedical Catalyst (BMC) grant from Innovate UK, the UK’s innovation agency.
Press Releases
£495k Grant Awarded by Innovate UK
ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced that the company has been awarded a highly competitive Biomedical Catalyst (BMC) grant from Innovate UK, the UK’s innovation agency.
Conferences
Scientific posters
Data debut: AACR 2023 Poster
ThirtyFiveBio were delighted to make our data debut at the American Association for Cancer Research (AACR) 2023 conference. CEO, James Westcott, presented our groundbreaking data at AACR 2023 in a scientific poster. Our team and network of academic institutions, research organizations, and industry partners have been developing and testing our innovative approach of antagonising GPR35...
Press Releases
ThirtyFiveBio Stealth Emergence
ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today emerged from stealth and announced that it will present the first data from its GPR35 antagonist program at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023.
